Cargando…

Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial

Advances in genomic technologies and an increased understanding of the molecular pathogenesis of cancer have resulted in development of new effective, mutation-targeted therapies. In turn, these informed the development of Master Trial designs to test these therapies. The Beat Acute Myeloid Leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Len, Levaux, Hugh, Levine, Ross L., Shah, Amit, Denmark, James, Hereema, Nyla, Owen, Melanie, Kalk, Spencer, Kenny, Nicholas, Vinson, Gene, Vergilio, Jo-Anne, Mims, Alice, Borate, Uma, Blum, William, Stein, Eytan, Gana, Theophilus J., Stefanos, Mona, Yocum, Ashley, Marcus, Sonja, Shoben, Abigail, Druker, Brian, Byrd, John, Burd, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332589/
https://www.ncbi.nlm.nih.gov/pubmed/33997942
http://dx.doi.org/10.1007/s43441-021-00277-w
_version_ 1783732922310721536
author Rosenberg, Len
Levaux, Hugh
Levine, Ross L.
Shah, Amit
Denmark, James
Hereema, Nyla
Owen, Melanie
Kalk, Spencer
Kenny, Nicholas
Vinson, Gene
Vergilio, Jo-Anne
Mims, Alice
Borate, Uma
Blum, William
Stein, Eytan
Gana, Theophilus J.
Stefanos, Mona
Yocum, Ashley
Marcus, Sonja
Shoben, Abigail
Druker, Brian
Byrd, John
Burd, Amy
author_facet Rosenberg, Len
Levaux, Hugh
Levine, Ross L.
Shah, Amit
Denmark, James
Hereema, Nyla
Owen, Melanie
Kalk, Spencer
Kenny, Nicholas
Vinson, Gene
Vergilio, Jo-Anne
Mims, Alice
Borate, Uma
Blum, William
Stein, Eytan
Gana, Theophilus J.
Stefanos, Mona
Yocum, Ashley
Marcus, Sonja
Shoben, Abigail
Druker, Brian
Byrd, John
Burd, Amy
author_sort Rosenberg, Len
collection PubMed
description Advances in genomic technologies and an increased understanding of the molecular pathogenesis of cancer have resulted in development of new effective, mutation-targeted therapies. In turn, these informed the development of Master Trial designs to test these therapies. The Beat Acute Myeloid Leukemia (BAML) Master Trial (Sponsor: The Leukemia & Lymphoma Society) tests several targeted therapies in patients aged ≥ 60 years with AML based on genomic profiling obtained within 7 days of study enrollment. We hypothesized that integrating operational strategies with new electronic technologies (e-technologies) might streamline the conduct and management of this Master Trial. BAML’s 5 core operational strategies revolve around the guiding principle of “patients first.” The e-technology platforms employed in BAML include: Clinical Oversight Platform: a central collaborative tool; e-Protocol/e-Source Upload/Electronic Data Capture Platform: digitizes the protocol, allows remote data monitoring, and collects/exports data in Study Data Tabulation Model format; and Data Review Platform: ingests data from different sources for clinical response and safety data reviews. The operational approaches, e-technologies and sponsor/contract research organization’s (CRO) expertise together allow: the complexity and size of the BAML Master Trial to be better managed; near real-time study data oversight; better collaboration, communication and training; improved data collection, enhanced transmission and accessibility; data integration, review and generation of reports; while maintaining data privacy, and compliance. Initial e-technology challenges were overcome through training, learning, discipline and adjustment. In conclusion, to successfully manage Master Trials, significant time should be spent re-evaluating, improving and developing new operational approaches. Clinical Trial Registration: Clinical Trials.gov Identifier: NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998.
format Online
Article
Text
id pubmed-8332589
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83325892021-08-20 Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial Rosenberg, Len Levaux, Hugh Levine, Ross L. Shah, Amit Denmark, James Hereema, Nyla Owen, Melanie Kalk, Spencer Kenny, Nicholas Vinson, Gene Vergilio, Jo-Anne Mims, Alice Borate, Uma Blum, William Stein, Eytan Gana, Theophilus J. Stefanos, Mona Yocum, Ashley Marcus, Sonja Shoben, Abigail Druker, Brian Byrd, John Burd, Amy Ther Innov Regul Sci Original Research Advances in genomic technologies and an increased understanding of the molecular pathogenesis of cancer have resulted in development of new effective, mutation-targeted therapies. In turn, these informed the development of Master Trial designs to test these therapies. The Beat Acute Myeloid Leukemia (BAML) Master Trial (Sponsor: The Leukemia & Lymphoma Society) tests several targeted therapies in patients aged ≥ 60 years with AML based on genomic profiling obtained within 7 days of study enrollment. We hypothesized that integrating operational strategies with new electronic technologies (e-technologies) might streamline the conduct and management of this Master Trial. BAML’s 5 core operational strategies revolve around the guiding principle of “patients first.” The e-technology platforms employed in BAML include: Clinical Oversight Platform: a central collaborative tool; e-Protocol/e-Source Upload/Electronic Data Capture Platform: digitizes the protocol, allows remote data monitoring, and collects/exports data in Study Data Tabulation Model format; and Data Review Platform: ingests data from different sources for clinical response and safety data reviews. The operational approaches, e-technologies and sponsor/contract research organization’s (CRO) expertise together allow: the complexity and size of the BAML Master Trial to be better managed; near real-time study data oversight; better collaboration, communication and training; improved data collection, enhanced transmission and accessibility; data integration, review and generation of reports; while maintaining data privacy, and compliance. Initial e-technology challenges were overcome through training, learning, discipline and adjustment. In conclusion, to successfully manage Master Trials, significant time should be spent re-evaluating, improving and developing new operational approaches. Clinical Trial Registration: Clinical Trials.gov Identifier: NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998. Springer International Publishing 2021-05-16 2021 /pmc/articles/PMC8332589/ /pubmed/33997942 http://dx.doi.org/10.1007/s43441-021-00277-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Rosenberg, Len
Levaux, Hugh
Levine, Ross L.
Shah, Amit
Denmark, James
Hereema, Nyla
Owen, Melanie
Kalk, Spencer
Kenny, Nicholas
Vinson, Gene
Vergilio, Jo-Anne
Mims, Alice
Borate, Uma
Blum, William
Stein, Eytan
Gana, Theophilus J.
Stefanos, Mona
Yocum, Ashley
Marcus, Sonja
Shoben, Abigail
Druker, Brian
Byrd, John
Burd, Amy
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
title Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
title_full Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
title_fullStr Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
title_full_unstemmed Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
title_short Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
title_sort streamlined operational approaches and use of e-technologies in clinical trials: beat acute myeloid leukemia master trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332589/
https://www.ncbi.nlm.nih.gov/pubmed/33997942
http://dx.doi.org/10.1007/s43441-021-00277-w
work_keys_str_mv AT rosenberglen streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT levauxhugh streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT levinerossl streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT shahamit streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT denmarkjames streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT hereemanyla streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT owenmelanie streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT kalkspencer streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT kennynicholas streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT vinsongene streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT vergiliojoanne streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT mimsalice streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT borateuma streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT blumwilliam streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT steineytan streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT ganatheophilusj streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT stefanosmona streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT yocumashley streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT marcussonja streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT shobenabigail streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT drukerbrian streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT byrdjohn streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial
AT burdamy streamlinedoperationalapproachesanduseofetechnologiesinclinicaltrialsbeatacutemyeloidleukemiamastertrial